Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Immuno-Oncology Europe 2019

Walter Ferlin's Biography

Walter Ferlin, CSO, Light Chain Bioscience

Walter Ferlin obtained a PhD in Immunology from the University of California, Davis & DNAX Research Institute, Palo Alto, California, working on the use of anti-CD40 antibodies as vaccine adjuvants. As a Postdoctoral Fellow at the CNRS institute in Sophia Antipolis, France, he focused on investigating tolerance mechanisms to islet antigens in diabetic mice where he developed peptide-MHC class II dimers as therapeutics to modulate antigen-specific T cell responses in autoimmune diabetes. In 2003 Walter joined Novimmune as the project leader for the development of a fully human antibody to interferon gamma. This antibody went on to become Novimmune’s first approved medicine for the treatment of primary hemophagocytic lymphohistiocytosis. Walter has also led several therapeutic bispecific antibody programs for cancer therapy now in clinical development. As Head of the Preclinical and Translational Sciences Department, Walter now oversees all preclinical and translational studies to support the pipeline of products in the immunotherapy for cancer.

Walter Ferlin Image

A Selective and Safe Bispecific Antibody Approach to Targeting CD47 Blockade on Tumor Cells

Tuesday, 29 October 2019 at 09:30

Add to Calendar ▼2019-10-29 09:30:002019-10-29 10:30:00Europe/LondonA Selective and Safe Bispecific Antibody Approach to Targeting CD47 Blockade on Tumor CellsImmuno-Oncology Europe 2019 in Rotterdam, The NetherlandsRotterdam, The

The CD47-signal regulatory protein alpha (SIRP-alpha) axis, originally discovered as a mechanism of self-recognition, has emerged as a novel innate immune check-point employed by cancer cells to escape immune surveillance. Over-expression of CD47 on a plethora of hematologic and solid cancers has been shown to be associated with poor prognosis. CD47 blockade is thus considered as an attractive strategy to redirect the host immune system toward eliminating cancer cells. A combination of the anti-CD20 monoclonal antibody (mAb), rituximab, and the anti-CD47 mAb, Hu5F9-G4 has shown clinical efficacy in patients with Non-Hodgkin lymphoma (NHL) treated. However, in parallel, due to the ubiquitous expression of CD47 on healthy cells, toxicity is observed limiting exposure which impairs clinical development of anti-CD47 mAbs. To harness the tumoricidal potential and avoid the liabilities of CD47 blockade, we have developed bispecific antibodies, co-targeting CD47 and a tumor associated antigen, for selective and safe blockade of CD47 on malignant cells.

Add to Calendar ▼2019-10-28 00:00:002019-10-29 00:00:00Europe/LondonImmuno-Oncology Europe 2019Immuno-Oncology Europe 2019 in Rotterdam, The NetherlandsRotterdam, The